Apocalyptic clinical pharmacology helps drug developers save resources and time through providing a framework for understanding the interaction of the drug under development with the biological system. This framework also helps answer questions from regulatory authorities who are evaluating the safety and efficacy of the drug. Making informed decisions throughout the drug development process requires […]
In early October, we held our D360 user group meeting (UGM) in Dublin, Ireland with the goal of fostering community among the users of our scientific informatics platform. In this blog post, I’ll share the UGM highlights and what’s coming up for the next UGM. Goals for this year’s meeting The meeting had three themes: […]
Watch this webinar with Nikunjkumar Patel, Shriram Pathak, and Rachel Rose to learn how the latest updates in the Simcyp Simulator v18 will help support developing safer, more effective medications.
Certara Launches BaseCase Toolkits to Facilitate Pharmaceutical and Medical Device Field Teams’ HCP and Payer Presentations
PRINCETON, NJ – Dec. 5, 2018 – Certara today announced the launch of its BaseCase Toolkits, an add-on to BaseCase Interactive which helps pharmaceutical and medical device field representatives better manage and utilize their resources for use during customer presentations.
PRINCETON, NJ – Nov. 28, 2018 – Certara today announced the launch of version 2.3 of its Trial Simulator software to help drug developers improve clinical trial design, resulting in greater likelihood of trial success.
Using Realistic Covariates with New Trial Simulator to Optimize Meropenem Dosing in Renally-impaired Children
Learn how to use trial simulation to anticipate risks and preview the range of expected results before millions in R&D dollars are spent, and subjects are exposed to experimental therapies.
Physiologically-based pharmacokinetics (PBPK) is a valuable resource to support decisions throughout drug development for sponsors and regulators. PBPK is used extensively to predict drug-drug interactions (DDIs), to inform dosing and clinical study design, to predict drug exposure, to predict variation in drug clearance, and to understand mechanisms of drug disposition. Virtual Twin technology, based on […]
Watch this webinar to learn why many major pharma organizations are investing in QSP for its potential to improve pharma R&D productivity.
PRINCETON, NJ – Nov. 14, 2018 – Certara today announced that it has been awarded two new dermal virtual bioequivalence grants by the US Food and Drug Administration (FDA).
Certara’s Evidence, Value & Access Specialists to Host Symposium on Automation in Public Health Decision-making and Present 18 Posters at ISPOR Europe
PRINCETON, NJ – Nov. 8, 2018 – Certara today announced that its Evidence, Value & Access team will host an educational symposium and present 18 research posters at ISPOR Europe 2018.